Hallmark Co-Targeting Combination Designer

A decision-support report that reads a tumor's existing molecular profile, maps which cancer hallmarks are actively driving that tumor, and ranks drug combinations that co-target two mechanistically distinct hallmarks. It turns the review's central hypothesis into a concrete regimen shortlist for tumor boards and combination-trial designers.